단백질 발현 시장 : 전략적 인사이트와 예측(2026-2031년)

The protein expression market is expected to achieve a 7.61% CAGR, increasing from USD 3.768 billion in 2025 to USD 5.852 billion in 2031.

The global protein expression market is experiencing steady growth, driven by the expansion of biologic drug pipelines, biosimilar development, and increasing investment in biopharmaceutical manufacturing. Protein expression technologies are essential for producing recombinant proteins used in therapeutics, research, and industrial applications. The market encompasses various expression systems, including prokaryotic, mammalian cell, insect cell, and yeast platforms, each suited to different protein types and applications. Demand conditions are increasingly shaped by the expansion of biologic drug pipelines, biosimilar development programs, cell and gene therapy research, and large-scale bioprocessing investments. The World Health Organization continues to identify biologics as an essential component of treatment for cancer, autoimmune disorders, diabetes, and other chronic diseases, while broader biosimilar adoption is expanding manufacturing activity across both developed and emerging markets. Value creation within the market is distributed unevenly across the value chain. High-margin opportunities are concentrated in mammalian expression platforms, proprietary vectors, specialized reagents, contract expression services, and process-development solutions. Purchasing decisions vary substantially across customer groups. Research laboratories prioritize speed, protocol compatibility, and reproducibility, while pharmaceutical and biotechnology companies place greater emphasis on expression yield, product quality, scalability, regulatory documentation, and process consistency.

Market Drivers

Expansion of Biologic Drug Development Pipelines

• Biologic medicines continue to gain importance across oncology, immunology, metabolic disease, and rare disease treatment. FDA biological approvals and ongoing clinical development programs require substantial recombinant protein production throughout discovery, preclinical testing, process development, and commercial manufacturing. This demand extends beyond finished therapeutics to include growth factors, enzymes, antibodies, and assay reagents. Large suppliers are responding by expanding bioproduction capabilities and manufacturing support services.

Rising Biosimilar Manufacturing Activity

• Biosimilars are becoming an important source of protein expression demand. According to the World Health Organization, biosimilars provide clinically equivalent alternatives to originator biologics while reducing treatment costs substantially. As additional biologic patents expire, manufacturers require expression systems capable of reproducing highly complex protein structures with consistent quality and yield. This trend is expanding demand for mammalian cell expression technologies, analytical characterization tools, process optimization services, and regulatory support capabilities.

Growth of Contract Development and Manufacturing Services

• Many biotechnology companies increasingly outsource protein production rather than invest in dedicated manufacturing infrastructure. Outsourcing reduces capital requirements and provides access to specialized expertise in cell-line development, upstream processing, downstream purification, and scale-up activities. Major life science companies continue expanding contract development and manufacturing capabilities, reflecting customer demand for integrated outsourcing models.

Increasing Use of Recombinant Proteins in Research Workflows

• Protein expression remains essential for drug target validation, structural biology, assay development, proteomics, and functional genomics. Universities, government laboratories, biotechnology firms, and pharmaceutical companies require continuous supplies of recombinant proteins and expression reagents to support discovery activities. Research demand differs from therapeutic manufacturing demand because customers prioritize flexibility, rapid turnaround, and broad protein availability rather than large-scale production economics.

Market Restraints

• Complexity of therapeutic protein production, particularly for proteins requiring precise folding and post-translational modifications, increases production costs and development timelines. Lengthy process-development and validation requirements extend procurement cycles and create switching costs. High capital and operating costs for advanced expression platforms, especially mammalian cell culture facilities, constrain smaller biotechnology companies. Technical variability and yield optimization challenges affect manufacturing economics. Pricing pressure in research-grade products creates margin pressure in certain product categories.

Technology and Segment Insights

By Expression System

• Mammalian cell expression represents the most commercially important segment because it supports production of complex therapeutic proteins requiring human-like post-translational modifications. Recombinant antibodies, fusion proteins, cytokines, and numerous biologics depend on mammalian hosts to achieve functional activity and regulatory acceptance. Buyer requirements in this segment differ markedly from those in prokaryotic expression. Pharmaceutical manufacturers prioritize glycosylation consistency, scalability, product quality, regulatory documentation, and process robustness. Competition centers on cell-line development capabilities, productivity improvements, media optimization, and process scalability. Prokaryotic systems remain important for simpler proteins and research applications. Insect cell, yeast, and other systems serve specific niches.

By Application

• Therapeutic applications represent the largest and fastest-growing segment, driven by biologics development and biosimilar manufacturing. Research applications provide a stable base of reagent and vector consumption. Industrial applications include enzyme production and other non-pharmaceutical uses.

By Product

• Reagents constitute a significant product category, including culture media, supplements, and detection reagents. Competent cells and expression vectors are essential tools for protein production. Services, including contract expression and process development, are a growing segment. Instruments support expression workflows.

Competitive and Strategic Outlook

• The competitive landscape features major life science and bioprocessing suppliers. Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Agilent Technologies, QIAGEN, Takara Bio, Inc., Promega Corporation, New England BioLabs, Inc., Oxford Expression Technologies, and Lucigen Corporation compete across different portions of the value chain. Competition is increasingly influenced by the ability to provide complete workflow solutions rather than standalone products. Customers seek suppliers capable of supporting discovery, development, scale-up, validation, and commercial manufacturing within a unified ecosystem. Strategic investment continues to focus on bioprocessing infrastructure, cell-line engineering, automation, analytical technologies, and service expansion. Barriers to entry are moderate to high in advanced therapeutic applications due to regulatory requirements, technical expertise, intellectual property, and customer qualification processes.
• Strategic developments include increasing product launches for optimized expression kits, acquisitions to expand enzyme and protease portfolios, and introductions of engineered host cell lines with improved productivity. Companies are expanding bioprocess design facilities and manufacturing infrastructure to support pharmaceutical and biotechnology customers. Partnerships and collaborations are strengthening research and development capabilities.

Conclusion

• The protein expression market is poised for steady growth, driven by biologics development, biosimilar expansion, and continued investment in biopharmaceutical manufacturing. The evolution toward integrated workflow solutions and specialized expression platforms is reshaping the competitive landscape. Companies that successfully support customers throughout the full protein development lifecycle, demonstrate process efficiency, and maintain regulatory expertise are expected to lead the market. Ongoing technological innovation and expanding biologics pipelines will further support adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PROTEIN EXPRESSION MARKET BY EXPRESSION SYSTEM

• 5.1. Introduction
• 5.2. Prokaryotic
• 5.3. Mammalian Cell
• 5.4. Insect Cell
• 5.5. Yeast
• 5.6. Others

6. PROTEIN EXPRESSION MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Therapeutic
• 6.3. Industrial
• 6.4. Research

7. PROTEIN EXPRESSION MARKET BY PRODUCT

• 7.1. Introduction
• 7.2. Reagents
• 7.3. Competent Cells
• 7.4. Expression Vectors
• 7.5. Services
• 7.6. Instruments

8. PROTEIN EXPRESSION MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Agilent Technologies, Inc.
• 10.2. Bio-Rad Laboratories
• 10.3. Thermo Fisher Scientific, Inc.
• 10.4. Merck Millipore (Merck KGaA)
• 10.5. New England BioLabs, Inc.
• 10.6. Promega Corporation
• 10.7. QIAGEN
• 10.8. Takara Bio, Inc.
• 10.9. Oxford Expression Technologies
• 10.10. Lucigen Corporation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations